23-valent pneumococcal polysaccharide vaccine
Trade name: pneumovax-23
Vaccineapproved
Approved
Nov 21, 1977
Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides. It is given by intramuscular or subcutaneous injection. — Wikipedia
Clinical trial activity
180 trials · 139 clinical orgs · 1 marketing orgs
Phase 1
43
Phase 2
82
Phase 3
47
Phase 4
49
Earliest trial started Nov 2, 1999 (NCT00001080)
Timeline
Indications
Approved for
Studied for
- Aged · Phase 4
- Aging · Early Phase 1
- Anemia, Sickle Cell · Phase 2
- Arthritis, Juvenile · Phase 2/Phase 3
- Arthritis, Rheumatoid · Phase 4
- Asthma · Phase 4
- Axial Spondyloarthritis · Phase 4
- Bone Marrow Transplantation · Phase 4
- Breast Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Common Variable Immunodeficiency · Phase 2
- COVID-19 · Phase 4
- Crohn Disease · Phase 4
- Deficiency Diseases · Phase 4
- Diabetes Mellitus, Type 1 · Phase 4
- Diphtheria · Phase 2/Phase 3
- Drugs, Investigational · Phase 2
- Haemophilus influenzae type b · Phase 2
- Healthy Volunteers · Phase 3
- Hematologic Diseases · Phase 2
- Hemolysis · Phase 4
- Hepatitis A · Phase 2
- Hepatitis B · Phase 2
- Herpes Zoster · Phase 3
- Herpes Zoster Vaccine · Phase 3
- HIV · Phase 4
- HIV-Associated Lipodystrophy Syndrome · Early Phase 1
- HIV Infections · Phase 4
- Immune Tolerance · Phase 2
- Immunization · Phase 2
- Immunosuppression Therapy · Phase 4
- Infections · Phase 1/Phase 2
- Inflammation · Early Phase 1
- Inflammatory Bowel Diseases · Phase 2
- Influenza, Human · Phase 4
- Kidney Failure, Chronic · Phase 4
- Kidney Transplantation · Phase 4
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 4
- Leukemia, Myeloid, Acute · Phase 4
- Liver Transplantation · Phase 4
- Lung Diseases · Phase 4
- Lupus Erythematosus, Systemic · Phase 4
- Lymphoma · Phase 4
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Non-Hodgkin · Phase 4
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 2
- Meningitis · Phase 2
- Meningococcal Infections · Phase 4
- Multiple Myeloma · Phase 2
- Multiple Sclerosis · Phase 3
- Multiple Sclerosis, Relapsing-Remitting · Phase 3
- Pertussis Vaccine · Phase 2
- Pneumococcal Infections · Phase 4
- Pneumococcal Vaccines · Phase 4
- Pneumonia · Phase 4
- Pneumonia, Bacterial · Phase 1/Phase 2
- Pneumonia, Pneumococcal · Phase 4
- Pneumonia, Staphylococcal · Phase 4
- Poliomyelitis · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 4
- Primary Immunodeficiency Diseases · Phase 4
- Psoriasis · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Respiratory Tract Diseases · Phase 1
- Respiratory Tract Infections · Phase 2
- Sjogren's Syndrome · Phase 4
- Splenectomy · Phase 2
- Streptococcal Infections · Phase 3
- Streptococcus pneumoniae · Phase 4
- Systemic Vasculitis · Phase 4
- Tetanus · Phase 2/Phase 3
- Thalassemia · Phase 4
- Transplants · Phase 4
- Urinary Bladder Neoplasms · Phase 1
- Vaccination · Phase 4
- Vaccines · Phase 4
- Whooping Cough · Phase 2/Phase 3
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Approval history
- approvedNov 21, 1977
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
Also known as
- 1,2,4-trichloro-5-((4-chlorophenyl)sulfinyl)benzene
- 23-valent pneumococcal capsular polysaccharide vaccine
- 23-valent pneumococcal polysaccharide vaccine
- 23-valent ppv
- 23-valent vaccine
- 23vppv
- 2,4,5,4'-tetrachlorodiphenylsulfoxide
- pneumo23
- pneumo 23
- pneumo-23
- pneumococcal 23 valent polysaccharide vaccine
- pneumococcal polysaccharide vaccine
- pneumococcal vaccine, polyvalent
- pneumococcal vaccine, polyvalent 23
- pneumovax
- pneumovax
- pneumovax
- pneumovax 23
- pneumovax 23
- pneumovax 23
- pneumovax 23
- pneumovax-23
- pneumovax-23
- pneumovax ii
- pneumovax ii
- pnu-imune 23
- polysaccharide anti- pneumococcal vaccine
- ppsv23
- ppv-23
- prodiax-23
- tetanus toxoid [tt]-containing adsorbed vaccine
- v110
- v110
- v110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06708286 | Phase 2/Phase 3 (Phase 3) | Dec 18, 2024 | Tianjin Cansino Biotechnology Inc |
| NCT06703203 | Phase 1/Phase 2 (Phase 2) | Aug 27, 2024 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT06474377 | Phase 1 | Jun 20, 2024 | China National Pharmaceutical Group, Government of China |
| NCT06271681 | Phase 4 | May 1, 2024 | Department of Veteran Affairs, Merck |
| NCT06678620 | Phase 2 | Apr 20, 2024 | Government of China |
| NCT06177912 | Phase 3 | Jan 17, 2024 | Merck |
| NCT06182124 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2023 | Pfizer |
| NCT06056050 | Phase 1 | Dec 6, 2023 | Tianjin Cansino Biotechnology Inc |
| NCT06678607 | Phase 1 | Nov 19, 2023 | Government of China |
| NCT07025876 | Early Phase 1 (Phase 1) | Nov 18, 2023 | Government of China |
| NCT06044077 | Phase 3 | Sep 8, 2023 | Government of China |
| NCT05982314 | Phase 1/Phase 2 (Phase 2) | Jul 17, 2023 | GPN Vaccines |
| NCT05827874 | Phase 1 | Apr 12, 2023 | — |
| NCT05731115 | Phase 4 | Feb 27, 2023 | Government of China, Sinovac Biotech Co., Ltd |
| NCT05696080 | Phase 3 | Feb 13, 2023 | Merck |
| NCT06314867 | Phase 3 | Jan 30, 2023 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT05667740 | Phase 1 | Jan 23, 2023 | GPN Vaccines, IDT Australia Ltd. |
| NCT05633992 | Phase 3 | Jan 10, 2023 | Merck |
| NCT05417165 | Phase 2 | Dec 31, 2022 | Ohio State University |
| NCT05622942 | Phase 1 | Dec 24, 2022 | Tianjin Cansino Biotechnology Inc |
Showing 20 of 180 trials
Page 1 / 9
Organizations
Research & Development (139)
139 organizations
Page 1 / 7